Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

This study has been terminated.
(Study terminated based on evaluation of safety data.)
Sponsor:
Information provided by (Responsible Party):
Ariad Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01650805
First received: July 18, 2012
Last updated: March 5, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: June 2021
  Estimated Primary Completion Date: June 2021 (Final data collection date for primary outcome measure)